All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (ID1379)

NICE GUIDANCE ISSUED August 2019

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 0717 – March 2017

Idelalisib (Zydelig®) 100 mg and 150 mg film-coated tablets

Submission by Gilead Sciences Ltd.

Recommendation of AWMSG

Idelalisib (Zydelig®) is recommended as an option for use as monotherapy for the treatment of adult patients with follicular lymphoma that is refractory to two prior lines of treatment.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered that idelalisib (Zydelig®) satisfied the AWMSG criteria for a medicine developed specifically for rare diseases.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2597), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.